Ligand Pharmaceuticals Incorporated (NASDAQ:LGND – Get Free Report) Director John Kozarich sold 1,575 shares of the firm’s stock in a transaction dated Wednesday, May 13th. The stock was sold at an average price of $223.50, for a total value of $352,012.50. Following the completion of the transaction, the director owned 41,786 shares of the company’s stock, valued at approximately $9,339,171. This represents a 3.63% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ligand Pharmaceuticals Trading Down 1.0%
Shares of LGND opened at $218.98 on Friday. Ligand Pharmaceuticals Incorporated has a twelve month low of $98.89 and a twelve month high of $247.38. The stock has a market cap of $4.39 billion, a PE ratio of 29.71, a P/E/G ratio of 1.79 and a beta of 1.20. The company has a quick ratio of 20.95, a current ratio of 21.28 and a debt-to-equity ratio of 0.45. The business’s 50-day moving average price is $214.39 and its 200-day moving average price is $201.77.
Ligand Pharmaceuticals (NASDAQ:LGND – Get Free Report) last released its quarterly earnings data on Thursday, May 14th. The biotechnology company reported $1.63 EPS for the quarter, missing analysts’ consensus estimates of $1.84 by ($0.21). The firm had revenue of $51.72 million during the quarter, compared to the consensus estimate of $59.10 million. Ligand Pharmaceuticals had a net margin of 55.95% and a return on equity of 16.19%. Ligand Pharmaceuticals’s revenue was up 14.1% compared to the same quarter last year. During the same quarter last year, the business posted $1.33 earnings per share. On average, equities analysts forecast that Ligand Pharmaceuticals Incorporated will post 5.46 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Check Out Our Latest Research Report on LGND
Hedge Funds Weigh In On Ligand Pharmaceuticals
Institutional investors have recently modified their holdings of the company. Fisher Asset Management LLC raised its stake in shares of Ligand Pharmaceuticals by 2.7% during the third quarter. Fisher Asset Management LLC now owns 108,926 shares of the biotechnology company’s stock worth $19,295,000 after acquiring an additional 2,860 shares in the last quarter. Envestnet Asset Management Inc. boosted its stake in shares of Ligand Pharmaceuticals by 16.6% in the 3rd quarter. Envestnet Asset Management Inc. now owns 31,915 shares of the biotechnology company’s stock valued at $5,653,000 after purchasing an additional 4,538 shares in the last quarter. Lisanti Capital Growth LLC boosted its stake in shares of Ligand Pharmaceuticals by 178.0% in the 3rd quarter. Lisanti Capital Growth LLC now owns 29,677 shares of the biotechnology company’s stock valued at $5,257,000 after purchasing an additional 19,002 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in shares of Ligand Pharmaceuticals by 59.5% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 541,845 shares of the biotechnology company’s stock valued at $95,982,000 after purchasing an additional 202,103 shares during the last quarter. Finally, Cibc World Market Inc. raised its position in Ligand Pharmaceuticals by 11.7% in the 3rd quarter. Cibc World Market Inc. now owns 59,131 shares of the biotechnology company’s stock worth $10,474,000 after purchasing an additional 6,209 shares during the period. 91.28% of the stock is currently owned by institutional investors.
About Ligand Pharmaceuticals
Ligand Pharmaceuticals, Inc is a biopharmaceutical company that acquires, develops and out-licenses proprietary technologies designed to help pharmaceutical and biotechnology companies discover and develop novel medicines. Operating primarily through its research services and royalty-generating businesses, Ligand focuses on building a diversified portfolio of technology platforms and partnering with industry leaders to advance therapeutic candidates across multiple disease areas.
The company’s product offerings center around several core platforms.
Featured Articles
- Five stocks we like better than Ligand Pharmaceuticals
- Be Ready: 3 Upcoming Catalysts Could Drive Oracle to Record Highs
- 2 Ways to Play the Big Pharma Patent Cliff
- YETI Rallies After Earnings Beat and Raised Outlook
- How the 3 Leading Quantum Firms Stack Up After Q1 Earnings
Receive News & Ratings for Ligand Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
